Please ensure Javascript is enabled for purposes of website accessibility

Government

Hard to swallow

When NPS Pharmaceuticals received federal approval to sell Gattex earlier this year, it was great news for those who suffer from short-bowel syndrome — a very rare disease.
It also was great news for the Bedminster company, which stands to benefit from $50 million in tax credit for developing this so-called orphan drug.

Read More »
[class^="wpforms-"]
[class^="wpforms-"]